Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/ https://www.ncbi.nlm.nih.gov/pubmed/30509237 http://dx.doi.org/10.1186/s12894-018-0416-6 |
_version_ | 1783377966209695744 |
---|---|
author | Fan, Liancheng Dong, Baijun Chi, Chenfei Wang, Yanqing Gong, Yiming Sha, Jianjun Pan, Jiahua Shangguan, Xun Huang, Yiran Zhou, Lixin Xue, Wei |
author_facet | Fan, Liancheng Dong, Baijun Chi, Chenfei Wang, Yanqing Gong, Yiming Sha, Jianjun Pan, Jiahua Shangguan, Xun Huang, Yiran Zhou, Lixin Xue, Wei |
author_sort | Fan, Liancheng |
collection | PubMed |
description | BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. RESULTS: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). CONCLUSIONS: These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-018-0416-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6276197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62761972018-12-06 Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Fan, Liancheng Dong, Baijun Chi, Chenfei Wang, Yanqing Gong, Yiming Sha, Jianjun Pan, Jiahua Shangguan, Xun Huang, Yiran Zhou, Lixin Xue, Wei BMC Urol Research Article BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. RESULTS: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). CONCLUSIONS: These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-018-0416-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-03 /pmc/articles/PMC6276197/ /pubmed/30509237 http://dx.doi.org/10.1186/s12894-018-0416-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Fan, Liancheng Dong, Baijun Chi, Chenfei Wang, Yanqing Gong, Yiming Sha, Jianjun Pan, Jiahua Shangguan, Xun Huang, Yiran Zhou, Lixin Xue, Wei Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title_full | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title_fullStr | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title_full_unstemmed | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title_short | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
title_sort | abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276197/ https://www.ncbi.nlm.nih.gov/pubmed/30509237 http://dx.doi.org/10.1186/s12894-018-0416-6 |
work_keys_str_mv | AT fanliancheng abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT dongbaijun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT chichenfei abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT wangyanqing abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT gongyiming abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT shajianjun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT panjiahua abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT shangguanxun abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT huangyiran abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT zhoulixin abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT xuewei abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors |